Alnylam Pharmaceuticals
ALNY
$303.05
-0.19%
Alnylam Pharmaceuticals is a biotechnology company and a pioneer in developing RNA interference (RNAi) therapeutics, a platform for silencing disease-causing genes. The company is a commercial-stage leader in the RNAi field with multiple approved products for rare diseases, including Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, and Oxlumo for primary hyperoxaluria type 1. The current investor narrative is focused on the company's transition to sustained profitability, driven by robust commercial growth, and the market's assessment of its valuation following a significant share price decline over the past year. Debate centers on whether the stock's pullback presents a compelling entry point for a profitable, high-growth platform company or reflects ongoing concerns about competition and the sustainability of its premium valuation.…
ALNY
Alnylam Pharmaceuticals
$303.05
Investment Opinion: Should I buy ALNY Today?
Rating & Thesis: Hold. While Alnylam's fundamentals are strengthening, the severe technical downtrend and high trailing valuation multiples create a high-risk entry point; investors should wait for evidence of a sustained bottom or clearer growth consistency before committing new capital. This view is tempered by the generally bullish analyst consensus and the attractive forward P/E of 21.8x.
Supporting Evidence: The recommendation is supported by four key data points: 1) Exceptional Q4 revenue growth of 84.95% YoY, 2) A successful transition to profitability with a Q4 net margin of 16.99%, 3) Strong liquidity evidenced by a current ratio of 2.76 and TTM FCF of $465M, and 4) A forward P/E of 21.8x that is reasonable for a commercial-stage biotech, especially when compared to the sector's growth-adjusted valuations. However, the extreme trailing P/E of 166x and the stock's position near 52-week lows counterbalance these positives.
Risks & Conditions: The two biggest risks are further multiple compression if growth falters and continued technical breakdown below the $283 support level. This Hold rating would upgrade to a Buy if the stock establishes a firm base above its 52-week low and reports another quarter of sequential revenue growth with stable margins, confirming the Q4 dip was an anomaly. It would downgrade to a Sell if revenue growth decelerates below 30% YoY or if net income turns negative again. The stock is currently fairly valued on a forward basis but remains overvalued on a trailing basis, reflecting a market in transition between punishing past multiples and pricing future earnings.
Sign up to view all
ALNY 12-Month Price Forecast
Alnylam is a fundamentally strong company trapped in a technically weak stock. The commercial success and path to profitability are clear, but the market is punishing it for past valuation excesses and fears about growth sustainability. The neutral stance reflects the high probability (50%) of a base case where the stock grinds higher as earnings materialize, but lacks a near-term catalyst for a sharp reversal. Confidence is medium due to the conflicting signals between operational metrics and price action. The stance would upgrade to bullish on a confirmed technical reversal above $350 coupled with a clean quarterly report, or downgrade to bearish on a break below $283 with deteriorating fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Alnylam Pharmaceuticals's 12-month outlook, with a consensus price target around $393.97 and implied upside of +30.0% versus the current price.
Average Target
$393.97
10 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
10
covering this stock
Price Range
$242 - $394
Analyst target range
The stock is covered by at least 10 analysts, with a consensus that appears bullish, as evidenced by recent institutional actions including multiple 'Buy' reiterations from firms like HC Wainwright, Chardan Capital, and Canaccord Genuity in Q1 2026. The average revenue estimate for the period is $11.74 billion, with a range from $10.96 billion to $13.72 billion, indicating high conviction in continued top-line growth. The average EPS estimate is $19.51, with a low of $17.83 and a high of $23.79, suggesting analysts expect significant earnings expansion. While a specific average price target is not provided in the data, the recent cluster of 'Buy' ratings and the high earnings estimates imply analyst sentiment is positive, viewing the recent sell-off as overdone relative to the company's fundamentals and commercial prospects. The wide range in revenue and EPS estimates signals a degree of uncertainty, typical for a commercial-stage biotech, regarding the exact trajectory of product sales and pipeline milestones. The recent downgrade by Jefferies from 'Buy' to 'Hold' in March 2026 introduces a note of caution, potentially reflecting concerns about near-term execution or valuation. Overall, the analyst coverage suggests a belief that the company's platform and commercial execution can drive substantial future earnings, supporting a positive long-term view despite recent stock price weakness.
Bulls vs Bears: ALNY Investment Factors
The evidence presents a stark contrast between deteriorating price action and strengthening fundamentals. The bear side currently has stronger technical evidence, with the stock in a severe downtrend and near 52-week lows, reflecting deep market skepticism. However, the bull case is grounded in concrete operational success: explosive revenue growth, a swing to profitability, and robust cash generation. The single most important tension in the investment debate is whether the market's negative sentiment, driven by valuation concerns and technical breakdown, will persist despite the company's demonstrable commercial execution and improving financial profile. The resolution hinges on whether upcoming earnings reports can demonstrate consistent, lump-free growth to justify the forward earnings multiple and catalyze a sentiment reversal.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue grew 84.95% year-over-year to $1.10 billion, driven by the commercial success of its RNAi therapeutics like Givlaari. This demonstrates the company's transition from a development-stage biotech to a high-growth commercial entity with a validated platform.
- Achieved Sustainable Profitability: The company reported a net income of $186.42 million in Q4 2025, a dramatic swing from a net loss of $83.76 million in Q4 2024, with a net margin of 16.99%. This signals a successful pivot to a profitable business model, supported by robust gross margins of 81.77%.
- Strong Free Cash Flow Generation: Alnylam generated $465.38 million in trailing twelve-month free cash flow and maintains a healthy current ratio of 2.76. This provides ample liquidity to internally fund its R&D pipeline and reduces reliance on external financing, a key de-risking factor.
- Attractive Forward Valuation: The stock trades at a forward P/E of 21.8x based on estimated EPS of $19.51, which is reasonable for a profitable, commercial-stage biotech with a proprietary platform. This multiple has compressed significantly from a trailing P/E of 166.0x, suggesting the recent sell-off has improved the valuation entry point.
Bearish
- Extreme Stock Price Weakness: The stock has declined 54.7% over the past year and 33.7% over the last six months, significantly underperforming the S&P 500 by 27.59%. Trading at $303.64, it is near its 52-week low of $283.10, indicating persistent negative sentiment and a 'falling knife' technical pattern that may not have bottomed.
- Elevated Trailing Valuation Multiples: Despite the price decline, the trailing P/E ratio remains extremely high at 166.0x, and the P/S ratio is 14.0x. These multiples imply the market expects flawless execution of future growth; any stumble could lead to severe multiple compression and further price declines.
- Quarterly Revenue Volatility: Revenue dipped sequentially from $1.25 billion in Q3 2025 to $1.10 billion in Q4 2025, following a sharp rise from $594 million in Q1. This lumpiness suggests potential unpredictability in product sales or royalty recognition, which could spook investors expecting smooth, linear growth.
- Leveraged Balance Sheet: The company's debt-to-equity ratio is 1.62, indicating a leveraged capital structure. While manageable given its cash flow, this leverage increases financial risk if revenue growth stalls or R&D costs escalate, potentially pressuring profitability.
ALNY Technical Analysis
The stock is in a pronounced downtrend, having declined 54.7% over the past year and 33.7% over the last six months. As of the latest close at $303.64, the price is trading near the lower end of its 52-week range ($283.10 to $495.55), at approximately 23% of the range, indicating the stock is deeply oversold and may be approaching a potential support zone. This positioning suggests the market has priced in significant negative sentiment, but also presents a potential value opportunity if fundamentals stabilize, though it remains a 'falling knife' scenario. Recent momentum shows a slight rebound, with the stock up 0.84% over the past month, which diverges from the severe longer-term downtrend and could signal a potential stabilization or short-term oversold bounce. However, the 3-month performance remains negative at -5.31%, and the stock has significantly underperformed the S&P 500, with a 1-year relative strength of -27.59%, indicating persistent weakness. Key technical levels are the 52-week low of $283.10 as immediate support and the 52-week high of $495.55 as major resistance. A decisive break below the 52-week low could trigger further selling, while a sustained move above the recent downtrend line would be needed to signal a reversal. The stock's beta of 0.30 indicates it is approximately 70% less volatile than the broader market, which is unusual for a biotech and suggests the recent price action has been driven more by stock-specific fundamental concerns than broad market moves.
Beta
0.27
0.27x market volatility
Max Drawdown
-42.0%
Largest decline past year
52-Week Range
$283-$496
Price range past year
Annual Return
-1.6%
Cumulative gain past year
| Period | ALNY Return | S&P 500 |
|---|---|---|
| 1m | +0.0% | -0.0% |
| 3m | -5.5% | +8.7% |
| 6m | -33.8% | +8.0% |
| 1y | -1.6% | +23.1% |
| ytd | -24.3% | +8.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALNY Fundamental Analysis
Revenue growth has been exceptionally strong, with Q4 2025 revenue of $1.10 billion representing a year-over-year increase of 84.95%. This explosive growth is driven by the commercial success of its RNAi therapeutics, particularly Givlaari, which contributed $160.67 million in the reported segment, and Onpattro at $70.76 million. The quarterly trend, however, shows volatility; revenue grew sequentially from $594 million in Q1 to $1.25 billion in Q3 before dipping to $1.10 billion in Q4, indicating potential lumpiness in product sales or royalty recognition. The company has achieved profitability, reporting a net income of $186.42 million for Q4 2025, with a net margin of 16.99%. Gross margins are robust at 81.77%, reflecting the high-margin nature of its therapeutics, and operating margins stand at a healthy 13.51%. The profitability picture has improved dramatically from a year ago, as evidenced by the Q4 2024 net loss of $83.76 million, signaling a successful transition to a sustainably profitable enterprise. The balance sheet shows a debt-to-equity ratio of 1.62, indicating a leveraged but manageable capital structure for a growth-stage biotech. The company generated strong free cash flow of $465.38 million on a trailing twelve-month basis and holds a current ratio of 2.76, demonstrating ample liquidity. The Return on Equity (ROE) is a very high 39.76%, which is impressive but may be inflated by the equity base; this metric, combined with the substantial free cash flow, suggests the company is generating attractive returns on its commercial platform and can internally fund its R&D pipeline.
Quarterly Revenue
$1.1B
2025-12
Revenue YoY Growth
+0.84%
YoY Comparison
Gross Margin
+0.75%
Latest Quarter
Free Cash Flow
$465383000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALNY Overvalued?
Given the company's positive net income of $186.42 million in the latest quarter, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E is extremely high at 166.0x, reflecting the market's forward-looking expectations and the recent profitability after a history of losses. The forward P/E is significantly lower at 21.8x, based on estimated EPS of $19.51, indicating the market expects a massive surge in earnings to justify the current price. This wide gap implies the market is pricing in the successful execution of Alnylam's growth trajectory and a rapid earnings ramp-up. Comparing to the broader biotechnology sector, which often trades at high multiples due to growth expectations, Alnylam's forward P/E of 21.8x is not excessive for a profitable commercial-stage biotech with a proprietary platform. The Price-to-Sales (P/S) ratio of 14.0x and EV/Sales of 9.1x also reflect a premium valuation, justified by its high gross margins and market leadership in RNAi. Historically, the stock's own valuation has compressed significantly from earlier periods; for instance, its P/E ratio in Q3 2025 was 59.7x, and it has traded at negative P/Es during loss-making quarters. The current trailing P/E of 166x, while elevated, is down from over 250x in recent quarters, suggesting some multiple contraction has already occurred alongside the price decline. Trading near its 52-week low, the stock is likely at the lower end of its historical valuation range, potentially offering a more attractive entry point if growth expectations are met.
PE
166.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -456x~71x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
92.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Alnylam's primary financial risk is its elevated valuation, with a trailing P/E of 166x and P/S of 14x, which makes the stock highly sensitive to any earnings disappointment or growth deceleration. The debt-to-equity ratio of 1.62 introduces leverage risk, though it is partially offset by strong TTM free cash flow of $465 million. Furthermore, quarterly revenue volatility—evidenced by the sequential dip from Q3 to Q4 2025—raises concerns about the predictability of product sales, which is critical for a stock trading on future growth expectations.
Market & Competitive Risks: The stock faces significant valuation compression risk; having declined 54.7% over the past year, it remains vulnerable to further de-rating if the market continues to reprice growth stocks or if sector rotation away from biotech persists. Its low beta of 0.30 suggests the sell-off is stock-specific, likely tied to concerns over competition in its niche rare disease markets or pipeline setbacks. The recent Jefferies downgrade to 'Hold' highlights emerging analyst caution regarding execution or valuation, which could limit near-term upside momentum.
Worst-Case Scenario: The most damaging scenario involves a combination of a clinical pipeline failure, slower-than-expected commercial uptake for its key products, and a broader biotech bear market. This could trigger a wave of analyst downgrades and force a re-rating to a more distressed valuation. The realistic downside would be a test and break of the 52-week low of $283.10, potentially extending to levels implied by the stock's maximum drawdown of -42.01%. From the current price of $303.64, this scenario could result in a loss of approximately 20-30%, driving the stock toward the $210-$240 range.
FAQ
The key risks are: 1) Valuation & Sentiment Risk: The stock's high trailing multiples make it vulnerable to severe compression if growth stumbles; its 54.7% annual decline shows sentiment is already fragile. 2) Execution Risk: Quarterly revenue volatility (e.g., the dip from Q3 to Q4 2025) raises questions about the predictability of commercial execution. 3) Financial Risk: A debt-to-equity ratio of 1.62 introduces leverage, though it is currently supported by strong cash flow. 4) Competitive & Pipeline Risk: As a biotech, it faces inherent risks from clinical trial failures or competitive threats in its niche rare disease markets. The valuation and sentiment risks are currently the most severe, as evidenced by the persistent price decline.
The 12-month forecast for ALNY is bifurcated, with a 50% probability base case target range of $320-$380, a 30% probability bull case target of $450-$495, and a 20% probability bear case target of $240-$283. The base case, which is most likely, assumes the company meets analyst expectations for revenue (~$11.74B) and EPS ($19.51), leading to a gradual recovery as the stock digests its severe decline. The key assumption is that quarterly growth stabilizes without major misses. The wide range reflects high uncertainty stemming from technical damage, valuation concerns, and the binary nature of biotech pipeline news.
ALNY's valuation is a tale of two metrics, making it neither clearly overvalued nor undervalued. On a trailing basis, it appears extremely overvalued with a P/E of 166.0x and a P/S of 14.0x. However, the forward P/E of 21.8x, based on analyst EPS estimates of $19.51, is reasonable for a profitable biotech with its growth profile. This wide gap indicates the market is paying a premium for expected future earnings growth. Compared to its own history, the valuation has compressed significantly from earlier peaks. Therefore, the stock is fairly valued based on forward earnings expectations but carries the risk of being overvalued if those expectations are not met.
ALNY presents a high-risk, high-potential-reward opportunity that is not a clear-cut 'good buy' for all investors at the current moment. For patient, risk-tolerant investors who believe in the RNAi platform, the forward P/E of 21.8x and the company's profitable growth trajectory could be attractive following a 54.7% price decline. However, the severe technical downtrend and elevated trailing multiples (P/E of 166x) mean it is still a 'falling knife' scenario. It is a good buy only for those with a long-term horizon who can withstand further volatility and are waiting for the stock to establish a technical base. A more conservative approach would be to wait for a confirmed breakout above the downtrend resistance.
ALNY is unequivocally suitable only for long-term investment, with a suggested minimum holding period of 3-5 years. Its low beta of 0.30 and lack of a dividend eliminate its appeal for short-term trading or income. The investment thesis is based on the long-term monetization of its RNAi platform and pipeline, which will take multiple years to unfold. The stock's extreme volatility and recent 54.7% drawdown also make it a poor candidate for short-term speculation, as sentiment-driven swings can be severe. Long-term investors can potentially look through the near-term technical weakness to the underlying commercial growth and profitability.